TriSalus Life Sciences

About TriSalus Life Sciences

TriSalus Life Sciences seeks to transform outcomes for patients with solid tumors by integrating innovative delivery technology with standard-of-care therapies and investigational immunotherapy. Their mission is to address critical barriers in the treatment of liver and pancreatic tumors, such as intratumoral pressure and immunosuppression, to improve patient outcomes.

Products & Services

Pressure-Enabled Drug Delivery™ (PEDD™) Platform:A transformative platform designed to overcome barriers like immunosuppression and delivery issues in liver and pancreatic tumors, used in combination with systemic immunotherapies such as checkpoint inhibitors.

Candidate Nelitolimod:An investigational therapy being studied as part of the pipeline for integration with the PEDD™ method to enable immunotherapies in liver and pancreatic tumors.

Pressure-Enabled Drug Delivery™ (PEDD™)

nelitolimod

Specialties

Innovative Drug Delivery Technology Immunotherapy for Solid Tumors Treatment of Liver and Pancreatic Tumors Overcoming Intratumoral Pressure Overcoming Immunosuppression immunotherapy delivery liver cancer treatment pancreatic cancer treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 40000000 MR: - FA: 40.0 million FAN: 40000000	D: 2026-02-20 FD: 2026-02-20	1 investors
2	RT: Debt T: - FT: Debt	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2025-02-03 FD: 2025-02-03	1 investors
3	RT: Debt T: - FT: Debt	A: 50000000 MR: - FA: up to $50 million FAN: 50000000	D: 2024-04-30 FD: 2024-04-30	1 investors

Public Offering Latest

2026-02-20

$40.0M

1 investor (Pro only)

Debt 2025-02-03

$10.0M

Debt 2024-04-30

$50.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mary Szela

Chief Executive Officer, President and Director

D

David Patience

Chief Financial Officer

R

Richard B. Marshak

Chief Commercial Officer

J

Jennifer L. Stevens

Chief Regulatory Officer

B

Bryan F. Cox

Chief of Research

R

Richard Marshall

Medical Director

View 5 more team members with Pro

Unlock Full Team Directory

Recent News